

# 2025 ISV ANNUAL CONGRESS

## ORAL PROGRAM

### TUESDAY 28 OCTOBER 2025

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:00-10:00 | REGISTRATION (Magnifica 4 & 5 Foyer – First Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 09:00-10:00 | WELCOME COFFEE Sponsored by GPN Vaccines (Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 10:00-10:10 | OPENING SESSION (Magnifica 4 & 5 – First Floor )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             | <p>WELCOME BY ISV PRESIDENT: Linda Klavinskis, <i>King's College London, UK</i></p> <p>CO-CHAIR REMARKS:<br/> Ed Rybicki, <i>University of Cape Town, South Africa</i><br/> Michael Schotsaert, <i>Icahn School of Medicine at Mount Sinai, USA</i><br/> Michelle Groome, <i>University of the Witwatersrand, South Africa</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 10:10-10:40 | STANLEY PLOTKIN LECTURE: (Magnifica 4 & 5 – First Floor )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             | <p>Session Chair: Linda Klavinskis, <i>King's College London, UK</i></p> <p>The Quest for a Safe and Effective HIV Vaccine: An Odyssey of Scientific Innovation and Perseverance<br/> Linda-Gail Bekker, <i>Desmond Tutu HIV Centre, University of Cape Town, South Africa</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 10:40-12:00 | PLENARY SESSION 1: Structure Based Vaccine Design (Magnifica 4 & 5 – First Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|             | <p>Session Chairs: Michael Schotsaert, <i>Icahn School of Medicine at Mount Sinai, USA</i><br/> Lakshmi Krishnan, <i>Life Sciences National Research Council Canada, Canada</i></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 10:40-11:05 | AI-based engineering of stabilized glycoproteins to improve vaccine efficacy and manufacturability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|             | Hans Langedijk, <i>ForgeBio, Netherlands</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 11:05-11:30 | Structure-Based Engineering of a <i>Borrelia burgdorferi</i> Vaccine Antigen Enhances Stability and Immunogenicity for Lyme Disease Prevention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|             | Kalvis Brangulis, <i>Riga Stradins University, Latvia</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 11:30-11:45 | Harnessing Chaperone in Structure-based Vaccine Design: RNA-based Regulated Assembly of VLPs and NPs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|             | Baik-Lin Seong, <i>Yonsei University, South Korea</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 11:45-12:00 | Structure-based vaccine design of viral hemagglutinin to induce broadly neutralizing responses against influenza A virus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|             | Nicholas Morano, <i>Columbia University, USA</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 12:00-13:30 | LUNCH Sponsored by Dynavax (Cultivar Restaurant Ground Floor)<br>(Additional Seating Bridge 1 & 2 – First Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 12:30-13:30 | Canadian Workshop on Specific New Technology (Omega – Ground Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|             | <p>Session Chair: Lakshmi Krishnan, <i>Vice President Life Sciences National Research Council Canada (NRC), Canada</i></p> <p>Canada's Health Emergency Readiness Agency and plans for pandemic resilience<br/> Kasondra White, <i>Director General, HERC/ISED, Canada</i></p> <p>NRC's VERO Cell technology as a platform for low-cost production of viral vaccines<br/> Chun Fang Shen, <i>Principal Research officer, National Research Council Canada, Canada</i></p> <p>Plant-made virus-like particle vaccines: A valuable platform both between and during pandemics<br/> Brian Ward, <i>Professor, McGill University and Chief Medical Officer, Aramis Biotechnologies, Canada</i></p> <p>Glycovax development model: a successful combination of commercial vaccine component production and proprietary innovative vaccines<br/> Élodie Pastural, <i>Director, Regulatory Affairs &amp; Clinical Development, GlycoVax Pharma, Canada</i></p> <p>Wrap-Up<br/> Lakshmi Krishnan, <i>Vice President Life Sciences National Research Council Canada (NRC), Canada</i></p> |

|             |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13:30-15:00 | <b>PLENARY SESSION 2: Systems Approaches to Next Generation Vaccines</b> (Magnifica 4 & 5 – First Floor)<br>Session Chairs: Ed Lavelle, <i>Trinity College Dublin, Ireland</i> ; Francesca Micoli, <i>GSK, Italy</i>                                                              |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
| 13:30-13:55 | <b>Systems Vaccinology</b><br>Bali Pulendran, <i>Stanford University, USA</i>                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
| 13:55-14:20 | <b>Systems Human Immunology: Immune Setpoint and Immune Health</b><br>John Tsang, <i>Yale University, New Haven, USA</i>                                                                                                                                                          |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
| 14:20-14:35 | <b>Breadth and Durability of RTS,S/AS01E-Induced Humoral Correlates of Protection in Controlled Human Malaria Infection and Field Efficacy Trials</b><br>Lenny Moise, <i>SeromYx Systems, USA</i>                                                                                 |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
| 14:35-14:50 | <b>Deciphering Immune Response Dynamics to the M72/AS01E Tuberculosis Vaccine Using Systems Transcriptomics</b><br>Taofeek Oluwaseun, <i>Crescent University, Nigeria</i>                                                                                                         |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
| 15:00-15:30 | <b>COFFEE BREAK Sponsored by Moderna</b> (Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                 |
| 15:30-17:30 | <b>CONCURRENT SESSION 1</b><br><i>(Magnifica 4 &amp; 5 – First Floor)</i><br><b>Next Generation Tools and Technologies for Vaccine Development</b><br>Session Chairs:<br>Branka Grubor-Bauk, <i>University of Adelaide, Australia</i><br>Lenny Moise, <i>SeromYx Systems, USA</i> | <b>CONCURRENT SESSION 2</b><br><i>(Vista – First Floor)</i><br><b>Defending the Future: Vaccines, Emerging Threats, and One Health</b><br>Session Chairs:<br>Alejandra Capozzo, <i>Universidad Abierta Interamericana, Buenos Aires, Argentina</i><br>Lars Frelin, <i>Karolinska Institutet, Sweden</i> | <b>CONCURRENT SESSION 3</b><br><i>(Omega – Ground Floor)</i><br><b>“Bright Sparks” in Vaccinology PhD student session</b><br>Session Chairs:<br>Ebony Gary, <i>The Wistar Institute, USA</i><br>Alec Freyn, <i>Moderna, USA</i> |
| 15:30-15:55 | <b>Advancing self-amplifying RNA as a vaccines platform</b><br>Robin Shattock, <i>Imperial College London, United Kingdom</i>                                                                                                                                                     | <b>Accelerating Vaccine Development for Future Outbreak: CEPI’s 100 Days Mission</b><br>Jakob Cramer, <i>Coalition for Epidemic Preparedness (CEPI), United Kingdom</i>                                                                                                                                 | <b>The Mexican High-Resolution HLA Database And Its Use To Select And Validate T-Cell Epitopes For Vaccines</b><br>Arturo Lian-Torres, <i>National Autonomous University of Mexico, Mexico</i><br><i>(15:30-15:40)</i>          |
| 15:55-16:20 | <b>Targeting Antimicrobial Resistance (AMR) with Innovative Vaccines</b><br>Michael Kowarik, <i>Limmatech, Switzerland</i>                                                                                                                                                        | <b>Crimean-Congo Hemorrhagic Fever Virus (CCHFV); From the lab bench to clinical trial</b><br>Ali Mirazimi, <i>Karolinska Institute, Sweden</i>                                                                                                                                                         | <b>Ionisable Lipids Synthesised from Biorenewable Waste as Delivery Vehicles and Adjuvants in mRNA Vaccines</b><br>Dylan Kairuz, <i>University of the Witwatersrand, South Africa</i><br><i>(15:40-15:50)</i>                   |
| 16:20-16:35 | <b>Toward the Development of a Pan-Beta-Coronavirus Vaccine</b><br>Jeffrey Ulmer, <i>TechImmune LLC, USA</i>                                                                                                                                                                      | <b>Safety, Tolerability and Immunogenicity of a First In Africa Vaccine Against Lassa Fever Virus, Synthetic Dna-Based Ino-4500, In a Phase 1b Clinical Trial In Healthy Ghanaian Adults</b><br>Mary Amoakoh-Coleman, <i>Noguchi Memorial Institute for Medical Research/University of Ghana, Ghana</i> | <b>Development of Stable Plant-Based Nanoparticle-Encapsidated mRNA Vaccines</b><br>Natalie Nel, <i>University of Cape Town, South Africa</i><br><i>(15:50-16:00)</i>                                                           |
| 16:35-16:50 | <b>Vaccines on Demand Are Within Reach: Validating Immunoinformatics-Driven Vaccine Design Through Preclinical and Clinical Applications</b><br>Anne De Groot,                                                                                                                    | <b>mRNA Vaccines Against Rift Valley Fever Virus and Marburg Virus</b><br>Alexander Bukreyev, <i>University of Texas Medical Branch at Galveston, USA</i>                                                                                                                                               | <b>Immunogenicity of Self-Amplifying RNA Vaccines Against Hepatitis B Virus</b><br>Nazia Samudh, <i>University of the Witwatersrand, South Africa</i><br><i>(16:00-16:10)</i>                                                   |

|             |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                           |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | <i>EpiVax Inc., USA</i>                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                           |
| 16:50-17:05 | <b>From Blood To Bench: Broad-Spectrum Bacterial Vaccine Targets Via Functional Antibody Discovery</b><br><b>Fadil Bidmos,</b><br><i>Imperial College London, United Kingdom</i>                                                                     | <b>Cross Reactivity Among Coronaviruses and The Development of Pan-Sarbecovirus and Pan-Betacoronavirus Vaccines Using a Protein Subunit Platform</b><br><b>Alyson Kelvin,</b><br><i>University of Calgary Faculty of Veterinary Medicine, Canada</i> | <b>Using Single Cell RNA Sequencing to Assess Immunological Responses in Quails Injected with Porcine Circovirus-Like Particles</b><br><b>Lekita Singh,</b><br><i>University of Cape Town, South Africa</i><br><i>(16:10-16:20)</i>                                       |
| 17:05-17:20 | <b>Development of a Complement-Dependent mRNA Vaccine Candidate for Gonorrhoea for LMICs Enabled by AI-Powered Antigen Selection</b><br><b>Frances Lees,</b><br><i>Afrigen Biologics, South Africa</i>                                               | <b>Targeted Ebola Vaccination Among Survivor Networks in the Democratic Republic of the Congo: A Feasibility Campaign Beyond Ebola Outbreak Context</b><br><b>Trésor Zola Matuvanga,</b><br><i>Université de Kinshasa, Congo-Kinshasa</i>             | <b>Low Vitamin B12 Levels and Anaemia Are Associated with Impaired Pneumococcal Vaccine Responses in Young Kenyan Children</b><br><b>Kelvin Mokaya Abuga,</b><br><i>KEMRI-Wellcome Trust Research Programme</i><br><i>(16:20-16:30)</i>                                   |
| 17:20-17:35 | <b>A FIH Dose-Escalation Trial of the Safety and Pharmacokinetics of Anti-SARS-CoV-2 DNA-Encoded Monoclonal Antibodies (DMAb) Formulated for Delivery by CELLECTRA in Healthy Adults</b><br><b>David Weiner,</b><br><i>The Wistar Institute, USA</i> | <b>Evaluation Of the Safety and Efficacy of a Crimean-Congo Hemorrhagic Fever Vaccine – A One Health Approach</b><br><b>Catherine Olal,</b><br><i>Univesrity of Texas Medical Branch at Galveston, USA</i>                                            | <b>Superior Protection and Prevention of Transmission Upon Influenza Infection By Adjuvanted Mucosal Vaccination in the Guinea Pig Influenza Model</b><br><b>Vivian Yan,</b><br><i>Icahn School of Medicine at Mount Sinai, USA</i><br><i>(16:30-16:40)</i>               |
|             |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                       | <b>Enhanced Mucosal SARS-CoV-2 Immunity After Heterologous Intramuscular mRNA Prime/Intranasal Protein Boost Vaccination with a Combination Adjuvant</b><br><b>Gabriel Laghlali,</b><br><i>Icahn School of Medicine at Mount Sinai, USA</i><br><i>(16:40-16:50)</i>       |
|             |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                       | <b>Seroprevalence, Associated Risk Factors, and Molecular Detection of Brucella spp. in Cattle, Sheep, Goats and Humans in Mvomero District, Morogoro, Tanzania</b><br><b>Emmanuel Lita</b><br><i>Sokoine University of Agriculture, Tanzania</i><br><i>(16:50-17:00)</i> |
|             |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                       | <b>Evaluation of Highly Conserved Burkholderia pseudomallei Proteins as pan-Burkholderia Vaccine Antigen Candidates</b><br><b>Alexander Badten,</b><br><i>University of Texas Medical Branch, USA</i><br><i>(17:00-17:10)</i>                                             |
|             |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                       | <b>Gut Microbiota Serve as Biomarkers to Predict Antibody Response to the Domestic Herpes Zoster Live Attenuated Vaccine in China</b>                                                                                                                                     |

|             |                                             |  |                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|---------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |                                             |  | <p><b>Simin Li,</b><br/><i>The Jiangsu Provincial Center for<br/>Disease Control and Prevention, China</i><br/>(17:10-17:20)</p> <p><b>Development of Crimean-Congo<br/>Haemorrhagic Fever Chadox2-<br/>Vectored Vaccines with First-In-<br/>Human, Phase 1 Clinical Trial<br/>Progression</b><br/><b>Jack Saunders,</b><br/><i>University of Oxford, United Kingdom</i><br/>(17:20-17:30)</p> |
| 17:35-18:00 | TRAINEE CONGRESS TRAVEL AWARD PRESENTATIONS |  | (Magnifica 1,2,3 -Ground Floor)                                                                                                                                                                                                                                                                                                                                                                |
| 18:00-20:00 | POSTER SESSION 1                            |  | (Magnifica 1,2,3 -Ground Floor)                                                                                                                                                                                                                                                                                                                                                                |
| 18:00-20:00 | WELCOME RECEPTION Sponsored by VisMederi    |  | (Magnifica 1,2,3 + Foyer-Ground Floor )                                                                                                                                                                                                                                                                                                                                                        |

# WEDNESDAY 29 OCTOBER 2025

|             |                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:00-08:30 | <b>MORNING COFFEE Sponsored by Mabtech</b> (Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 08:30-09:00 | <b>MORNING SESSION</b> (Magnifica 4 & 5 – First Floor)<br><b>Session Chair: Jeff Ulmer, TechImmune LLC, USA</b><br><br><b>KEYNOTE LECTURE:</b><br><b>Nucleoside-modified mRNA-LNP therapeutics</b><br><b>Drew Weissman, University of Pennsylvania, USA</b>                         |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 09:00-10:35 | <b>PLENARY SESSION 3: Climate, Environment, and Vaccination</b> (Magnifica 4 & 5 – First Floor)<br><b>Responding to a Changing World</b><br><b>Session Chairs: Ed Rybicki, University of Cape Town, South Africa</b><br><b>Sarah Gilbert, University of Oxford, UK</b>              |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 09:00-09:25 | <b>Using genomics to characterize and respond to climate amplified disease and epidemics</b><br><b>Tulio de Oliveira, University of Stellenbosch, South Africa</b>                                                                                                                  |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 09:25-09:50 | <b>Dengue: global epidemiology and strategies for prevention and control</b><br><b>Fernanda Boulos, Butantan Institute, Brazil</b>                                                                                                                                                  |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 09:50-10:05 | <b>A Multi-Antigen DNA Vaccine Induces Mucosal Immune Protection From Valley Fever, A Respiratory Fungal Disease that is Spreading Due to Climate Change</b><br><b>Deborah Fuller, University of Washington, USA</b>                                                                |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 10:05-10:20 | <b>A Phase III randomized controlled multi-centre trial evaluating the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria</b><br><b>Angela Gwakisa, Ifakara Health Institute (IHI), Tanzania</b>                                                     |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 10:20-10:35 | <b>Tracking the Spread of Antimalarial Drug Resistance: Molecular Markers Analysis in Central and South-Eastern Senegal, 2019</b><br><b>Mamadou Yade, International Center for Research and Training on Applied Genomics and Health Surveillance (CIGASS), Mali</b>                 |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 10:35-11:00 | <b>COFFEE BREAK Sponsored by Sanofi</b> (Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                            |
| 11:00-12:35 | <b>CONCURRENT SESSION 4</b><br><b>(Magnifica 4 &amp; 5 – First Floor)</b><br><b>MPOX AND OTHER VECTORED VACCINES</b><br><b>Session Chairs:</b><br><b>Anna-Lise Williamson,</b><br><i>University of Cape Town, South Africa</i><br><b>Kai Dallmeier</b><br><i>KU Leuven, Belgium</i> | <b>CONCURRENT SESSION 5</b><br><b>(Vista – First Floor)</b><br><b>VACCINES AND IMMUNOTHERAPEUTICS AGAINST MUCOSAL PATHOGENS</b><br><b>Session Chairs:</b><br><b>Adam Cunningham,</b><br><i>University of Birmingham, UK</i><br><b>Denise Doolan,</b><br><i>University of Queensland, Australia</i> | <b>CONCURRENT SESSION 6</b><br><b>(Omega – Ground Floor)</b><br><b>“Bright Sparks” in Vaccinology ECR session</b><br><b>Session Chairs:</b><br><b>Linda Klavinskis</b><br><i>King’s College London, UK</i><br><b>David Weiner</b><br><i>The Wistar Institute, USA</i>                      |
| 11:00-11:25 | <b>The Emergence of Mpox Clade Ib, an accident waiting to happen</b><br><b>Laurens Liesenborghs,</b><br><i>Institute for Tropical Medicine, Antwerp, Belgium</i>                                                                                                                    | <b>Shigella Vaccines – Advancing Innovation to Combat a Global Health Threat</b><br><b>Francesca Micoli,</b><br><i>GSK, Italy</i>                                                                                                                                                                  | <b>Cytomegalovirus viral Fc gamma receptors as vaccine antigens to enhance anti-viral Fc-mediated effector antibody functions</b><br><b>Claire Otero</b><br><i>Weill Cornell Medicine, USA</i><br><i>(11:00-11:10)</i>                                                                     |
| 11:25-11:50 | <b>The Role of MVA-BN in Mpox Management: Current Data and Future Directions</b><br><b>Melvin Sanicas,</b><br><i>Bavarian Nordic, Switzerland</i>                                                                                                                                   | <b>Humoral and mucosal immunity, and retention of attenuated phenotype: results of a phase 1 study of novel type 1 and 3 OPVs</b><br><b>Chris Gast,</b><br><i>PATH, USA</i>                                                                                                                        | <b>Oral Immunization with Filoviral-Like Particles Elicits Ebola-Specific Humoral and Cellular Immune Responses and Confers Protection from Ebola Challenge In Mice</b><br><b>Juan Garcia-Bernalt Diego,</b><br><i>Centro de investigación Hospital Universitario 12 de Octubre, Spain</i> |

|             |                                                                                                                                                                                                  |                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                           |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |                                                                                                                                                                                                  |                                                                                                                                                                                                                               | (11:10-11:20)                                                                                                                                                                                                                                                                             |
| 11:50-12:05 | <b>Genetic Diversity and Population Structure of Mpox Virus In Africa: Identifying Key Targets For Vaccine Development</b><br><b>Abubakar Woziri,</b><br><i>Ahmadu Bello University, Nigeria</i> | <b>A Potent Monoclonal Antibody Against Gonococcal Lipooligosaccharide with Enhanced Effector Function and Half-Life</b><br><b>Davinder Gill,</b><br><i>StiRx Inc, USA</i>                                                    | <b>Intranasal Spike Protein with Mucosal Combination Adjuvant: Potential for Mucosal Booster Vaccination After Intramuscular mRNA Vaccine Against SARS-CoV-2</b><br><b>Seokchan Park,</b><br><i>Icahn School of Medicine at Mount Sinai, USA</i><br>(11:20-11:30)                         |
| 12:05-12:20 | <b>Utilizing the VSV Vector Approach for Emerging Infections Disease Vaccine Development</b><br><b>Marija Zaric,</b><br><i>IAVI, United Kingdom</i>                                              | <b>Swab And Spray: A Proposal for Future Precision Immunization Against Respiratory Infections Through Infection Risk Assessment and Nasal Vaccination</b><br><b>Ling Chen,</b><br><i>Guangzhou Medical University, China</i> | <b>Age-Dependent Immune Profiling and Spatial Resolution of HIV-1 Subtype C Reservoirs in Human Tonsillar Tissues</b><br><b>Faiaz Shaik Abdool,</b><br><i>Africa Health Research Institute, South Africa</i><br>(11:30-11:40)                                                             |
| 12:20-12:35 | <b>A New Single-Virus MMR Vaccine: Measles-Based Vector Expressing Rubella and Mumps Antigens</b><br><b>Phanramphoei Frantz</b><br><i>Institut Pasteur, France</i>                               | <b>Engineered Design of Mucus Penetration Nanoparticles for Inhalable Vaccines</b><br><b>Bingbing Sun,</b><br><i>Dalian University of Technology, China</i>                                                                   | <b>Empty Vector Plasmid DNA in Lipid Nanoparticles is a Potent Adjuvant for Recombinant Protein Vaccines</b><br><b>Nicholas Tursi,</b><br><i>The Wistar Institute, USA</i><br>(11:40-11:50)                                                                                               |
|             |                                                                                                                                                                                                  |                                                                                                                                                                                                                               | <b>M72/AS01E Vaccination Boosts Polyfunctional Effector Memory CD4+ T Cell Populations That May Serve as Immune Correlates of Protection</b><br><b>Sharon Khuzwayo,</b><br><i>Cape Town HVTN Immunology, South Africa</i><br>(11:50-12:00)                                                |
|             |                                                                                                                                                                                                  |                                                                                                                                                                                                                               | <b>Durability and Functional Profile of T Cell Responses to SARS-CoV-2 After Multiple Vaccinations in People Living with HIV</b><br><b>Maxine Hoft,</b><br><i>University of Cape Town, South Africa</i><br>(12:00-12:10)                                                                  |
|             |                                                                                                                                                                                                  |                                                                                                                                                                                                                               | <b>Development of a Genotype-Matched Newcastle Disease DNA Vaccine Candidate Adjuvanted with IL-28b for the Control of Targeted Velogenic Strains of Newcastle Disease Virus in Africa</b><br><b>Charlie Amoia,</b><br><i>SACIDS Foundation for One Health, Tanzania</i><br>(12:10-12:20) |
|             |                                                                                                                                                                                                  |                                                                                                                                                                                                                               | <b>Development of Plant-Made Ms-1797: A Low-Cost Monoclonal Antibody for Malaria Prevention</b><br><b>Christine Bulaon,</b><br><i>Baiya Phytopharm Co., Ltd.,</i>                                                                                                                         |

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  |                                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------|
|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  | <i>Thailand<br/>(1220-1230)</i> |
| 12:35-14:00 | <b>LUNCH Sponsored By Pfizer</b> (Cultivar Restaurant Ground Floor)<br><b>(Additional Seating Bridge 1 &amp; 2 – First Floor)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  |                                 |
| 13:00-14:00 | <b>ROUND TABLE DISCUSSION: Building Sustainable mRNA Vaccine Capacity in LMICs</b> (Omega-Ground Floor)<br>Organizers: <b>Robin Shattock</b> / <b>Sarah Joseph</b> , <i>Imperial College London, UK</i><br><b>Pierre Gsell</b> , <i>WHO, Switzerland</i><br><br>Discussion Chair: <b>Robin Shattock</b> , <i>Imperial College London, UK</i><br><br>Participants:<br><b>Caryn Fenner</b> , <i>Afrigen, South Africa</i><br><b>Ebrahim Mohammed</b> , <i>Biovac, South Africa</i><br><b>Pierre Gsell</b> , <i>WHO, Switzerland</i><br><b>Ncaise Ndembi</b> , <i>IVI, Rwanda</i><br><b>Drew Weissman</b> , <i>University of Pennsylvania, USA</i><br><b>Sina Mozaffari-Jovin</b> , <i>Max-Planck Institute, Germany</i> |  |                                 |
| 13:00-14:00 | <b>PANEL DISCUSSION FOR ECR'S: Vaccines We Have Not Considered Yet – Vaccines for Space Travel</b> (Vista-First Floor)<br><br><b>Panelists:</b><br><b>Nicole Steinmetz</b> <i>University of California, USA</i><br><b>Alejandra Capozzo</b> , <i>Universidad Abierta Interamericana, Buenos Aires, Argentina</i>                                                                                                                                                                                                                                                                                                                                                                                                      |  |                                 |
| 14:00-15:30 | <b>POSTER SESSION 2</b> (Magnifica 1,2,3 -Ground Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |  |                                 |
| 14:30-15:30 | <b>ISV ANNUAL GENERAL MEETING</b> (Omega-Ground Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                 |
| 15:30-16:00 | <b>COFFEE BREAK Sponsored By Bavarian Nordic</b> (Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  |                                 |
| 16:00-17:35 | <b>PLENARY SESSION 4: Maternal and Infant Vaccination in Preventing Disease</b> (Magnifica 4 & 5 – First Floor)<br>Session Chairs: <b>Michelle Groome</b> , <i>University of the Witwatersrand, South Africa</i><br><b>Neil Almond</b> , <i>MHRA (NIBSC), UK</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |                                 |
| 16:00-16:25 | <b>Opportunities and challenges in prevention of respiratory syncytial virus in infants through maternal immunization</b><br><b>Shabir Madhi</b> , <i>University of the Witwatersrand, South Africa</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |  |                                 |
| 16:25-16:50 | <b>New Horizon of RSV Lower Respiratory Disease in infants: Real-World Impact with a Monoclonal Antibody in all Infants</b><br><b>Danilo Casimiro</b> , <i>Vaccine R&amp;D, Sanofi, USA</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |                                 |
| 16:50-17:05 | <b>How Can We Unlock Inflationary CMV-Specific T Cell Immunity During Pregnancy in the Design of a Maternal Vaccine Against CMV</b><br><b>Brandon Paarwater</b> , <i>Stellenbosch University, South Africa</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |  |                                 |
| 17:05-17:20 | <b>Embarking on a Path of Clinical Development of A Haemophilus Influenzae Type A Vaccine</b><br><b>Joanne Langley</b> , <i>Dalhousie University, Canada</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                 |
| 17:20-17:35 | <b>Long-Term Immunogenicity of a Single Dose Compared with a Two-Dose Primary Series Followed by a Booster Dose Of 10- Or 13-Valent Pneumococcal Conjugate Vaccines In South African Children Up To 5 Years Of Age: An Open-Label, Randomised, Non-Inferiority Trial</b><br><b>Daniel Kapelus</b> , <i>University of the Witwatersrand, South Africa</i>                                                                                                                                                                                                                                                                                                                                                              |  |                                 |
| 18:00       | <b>GROUP PHOTO &amp; PICK UP FOR GALA DINNER</b> (Protea Hotel Front Entrance)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |  |                                 |

| THURSDAY 30 OCTOBER 2025 |                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:00-08:30              | MORNING COFFEE Sponsored by Inovio Pharmaceuticals, Inc(Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 08:30-09:00              | <b>MORNING SESSION</b> (Magnifica 4 & 5 – First Floor)<br><b>Session Chair: Margaret Liu, ProTherImmune &amp; Karolinska Institutet, USA &amp; Sweden</b><br><br><b>KEYNOTE LECTURE: Novel TB vaccines: is control of the global epidemic on the horizon?</b><br><b>Willem Hanekom, Africa Health Research Institute, South Africa</b> |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 09:00-10:35              | <b>PLENARY SESSION 5: Progress in Therapeutic Cancer Vaccines</b> (Magnifica 4 & 5 – First Floor)<br><b>Session Chairs: David Weiner, The Wistar Institute, USA</b><br><b>Barbara Felber, National Cancer Institute, USA</b>                                                                                                           |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 09:00-09:25              | <b>RNA Vaccines for Pancreatic Cancer</b><br><b>Vinod Balachandran, Memorial Sloan Kettering Cancer Center, USA</b>                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 09:25-09:50              | <b>NanoEngineering gone viral: plant virus-based immunotherapy</b><br><b>Nicole Steinmetz, University of California, USA</b>                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 09:50-10:05              | <b>An mRNA Cancer Vaccine Encoding a DC-Targeting Peptide and Flagellin Induces Potent Antitumor Responses in a Murine Model</b><br><b>Joon Haeng Rhee, Chonnam National University, South Korea</b>                                                                                                                                   |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 10:05-10:20              | <b>Novel Nanokine-Tm Technologies to Control Regulatory Immunity for New Immunotherapy Treatments for Infectious Disease and Oncology</b><br><b>Ursula Gompels, Virothera Ltd, United Kingdom</b>                                                                                                                                      |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 10:20-10:35              | <b>Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 &amp; 11 Recurrent Respiratory Papillomatosis</b><br><b>Jacqueline Shea, Inovio Pharmaceuticals, Inc., USA</b>                                                                                          |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 10:35-10:55              | COFFEE BREAK Sponsored By eubiologics (Magnifica 1,2,3 Foyer-Ground Floor)                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                   |
| 11:00-12:45              | <b>CONCURRENT SESSION 7</b><br><b>(Magnifica 4 &amp; 5 – First Floor)</b><br><b>What's new in HIV vaccine Development</b><br><b>Session Chairs:</b><br><b>Shan Lu,</b><br><i>Worcester HIV Vaccine (WHV)</i><br><i>and UMASS Chan Medical School,</i><br><i>USA</i><br><b>Robin Shattock,</b><br><i>Imperial College London, UK</i>    | <b>CONCURRENT SESSION 8</b><br><b>(Vista – First Floor)</b><br><b>Unlocking immunity: Mechanistic insights driving Next Gen Vaccine design</b><br><b>Session Chairs:</b><br><b>Michael Schotsaert,</b><br><i>Icahn School of Medicine at Mount Sinai, USA</i><br><b>Frédéric Tangy,</b><br><i>Instiut Pasteur, France</i> | <b>CONCURRENT SESSION 9</b><br><b>(Omega – Ground Floor)</b><br><b>Public Health Approaches in Vaccinology</b><br><b>Session Chairs:</b><br><b>Davinder Gill,</b><br><i>StiRx Inc, USA</i><br><b>Tim Hirst,</b><br><i>GPN Vaccines, Australia</i> |
| 10:55-11:20              | <b>Targeting HIV broadly neutralizing antibody precursors in humans with atomic precision</b><br><b>Rogier Sanders,</b><br><i>University of Amsterdam,</i><br><i>The Netherlands</i>                                                                                                                                                   | <b>Focusing on conserved immunogenic regions results in broad breadth of Betacoronavirus virus T cell recognition</b><br><b>Alba Grifoni,</b><br><i>La Jolla Institute, USA</i>                                                                                                                                           | <b>Can vaccines move cholera ahead of the epidemic curve</b><br><b>Lucille Blumberg,</b><br><i>Nat. Inst. for Communicable Diseases, South Africa</i>                                                                                             |
| 11:20-11:45              | <b>Characterizing HIV breakthrough infections from large antibody-mediated prevention trials: Mechanisms of escape and implications for vaccine design</b><br><b>Carolyn Williamson,</b><br><i>University of Cape Town,</i><br><i>South Africa</i>                                                                                     | <b>Interferons and inflammasomes as mediators of adjuvant induced immunity</b><br><b>Ed Lavelle,</b><br><i>Trinity College Dublin, Ireland</i>                                                                                                                                                                            | <b>Harnessing respiratory virus vaccines for public health impact</b><br><b>Cheryl Cohen,</b><br><i>University of Witwatersrand,</i><br><i>South Africa</i>                                                                                       |

|             |                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11:45-12:00 | <b>Engineering Cytoplasmic Domains of Stabilized mRNA Env Immunogens Enhances Neutralizing Response</b><br><b>Edward Kreider,</b><br><i>University of Pennsylvania School of Medicine, USA</i>                                                                                                                                                                                          | <b>CD4+ T Cell Responses After mRNA-1273 SARS-CoV-2 Vaccination in People Living with HIV are Associated with Risk of COVID-19</b><br><b>Erica Andersen-Nissen,</b><br><i>Cape Town HVTN Immunology Laboratory, South Africa</i> | <b>Neutralizing Antibody Titers Predict Protection from Virus Transmission in a Cohort of Household Members with Documented Exposure to SARS-CoV-2</b><br><b>Luka Cicin-Sain,</b><br><i>Helmholtz Centre for Infection Research, Germany</i> |
| 12:00-12:15 | <b>Heterologous Immunization with Improved Hiv-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After Shiv Challenge</b><br><b>Rosamund Chapman,</b><br><i>University of Cape Town, South Africa</i>                                                                                                                          | <b>Tolerogenic mRNA-Lipid Nanoparticle Vaccines for Autoimmune Disease</b><br><b>Jilian Melamed,</b><br><i>University of Pennsylvania, USA</i>                                                                                   | <b>Factors Influencing Maternal Vaccine Uptake Among Adults in Johannesburg, South Africa: A Qualitative Study</b><br><b>Mulalo Mashamba,</b><br><i>Vaccines and Infectious Diseases Analytics Research Unit, South Africa</i>               |
| 12:15-12:30 | <b>Concurrent Schistosoma Mansoni Infection Suppresses Induction Of HIV-1 Neutralizing Antibodies in a Dna/Mva/Gp140 Env Vaccine Regimen in Rhesus Macaques</b><br><b>Gerald Chege,</b><br><i>South African Medical Research Council, South Africa</i>                                                                                                                                  | <b>Convergent and Clonotype-Enriched Mutations Drive Affinity Maturation of a Public Antibody</b><br><b>Vishal Rao,</b><br><i>Icahn School of Medicine at Mount Sinai, USA</i>                                                   | <b>Perception of Disease Severity Drives Willingness for Cholera Vaccine Uptake: Evidence From a Covid-19 Surveillance Cohort</b><br><b>Andrew Musyoki,</b><br><i>Sefako Makgatho Health Sciences University, South Africa</i>               |
| 12:30-12:45 | <b>Stabilized HIV Envelope Trimer DNA/LION Vaccines Induce Autologous Tier 2 Neutralizing Antibodies and Strong Cytotoxic CD8 Cells in Macaques</b><br><b>Margherita Rosati,</b><br><i>NIH/NCI, USA</i>                                                                                                                                                                                 | <b>Harnessing The Potential of mRNA Vaccines Against Hepatitis C Virus</b><br><b>Branka Grubor-Bauk,</b><br><i>University of Adelaide, Australia</i>                                                                             | <b>Mpox Vaccination in Africa: One Year On - Lessons and Milestones From the Continental Response</b><br><b>Charles Ibeneme,</b><br><i>Africa Centers for Disease Control and Prevention, Zambia</i>                                         |
| 12:45-14:00 | <b>LUNCH Sponsored By Vaxxas</b> (Cultivar Restaurant Ground Floor)<br>(Additional Seating Bridge 1 & 2 – First Floor)                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |
| 13:00-14:00 | <b>VAXXAS WORKSHOP: ENABLING AT-HOME VACCINATION: TECHNOLOGIES FOR SELF-ADMINISTRATION</b> (Omega-Ground Floor)                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |
| 13:00-14:00 | <b>CAREER DEVELOPMENT WORKSHOP</b> (Vista-First Floor)<br><b>Panelists:</b><br><b>Jamie Pillaye,</b> <i>BactiVac Network, UK</i><br><b>Elloise du Toit,</b> <i>GARP-SA, South Africa</i><br><b>Maranyane Hapiloe,</b> <i>Afrigen, South Africa</i><br><b>Erica Andersen-Nissen,</b> <i>Cape Town HVTN Immunology Laboratory, South Africa</i><br><b>Alec Freyn,</b> <i>Moderna, USA</i> |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |
| 14:00-14:30 | <b>AWARD CEREMONY</b> (Magnifica 4 & 5 – First Floor)                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |
| 14:30-14:55 | <b>ISV PAPER OF THE YEAR:</b><br>Chair: <b>Linda Klavinskis,</b> <i>King's College London, UK</i><br><b>Development of a quadrivalent mRNA-lipid nanoparticle vaccine to elicit cross-reactive immune responses against diverse Orthopoxviruses</b><br><b>Alec Freyn,</b> <i>Moderna, USA</i>                                                                                           |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |
| 14:55-16:05 | <b>PLENARY SESSION 6: Cutting-Edge Innovations in Vaccine Manufacturing: The Future of Scalable Production</b> (Magnifica 4 & 5 – First Floor)<br><b>Session Chairs:</b> <b>Manon Cox,</b> <i>NextWaveBio, USA</i><br><b>Danilo Casimiro,</b> <i>Vaccine R&amp;D, Sanofi, USA</i>                                                                                                       |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                              |

|             |                                                                                                                                                                                                                                                                                                                            |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 14:55-15:20 | Advancing sustainable local vaccine manufacturing through end-to-end project support<br>Nicaise Ndembi, <i>DDG, IVI, Africa</i>                                                                                                                                                                                            |
| 15:20-15:45 | Development of bacterial vaccines and strategic collaboration for regional vaccine manufacturing.<br>Shin-Hee Jun, <i>EuBiologics, South Korea</i>                                                                                                                                                                         |
| 15:45-16:05 | <div>CLOSING SESSION (Magnifica 4 &amp; 5 – First Floor)</div> <div>2025 Congress Reflections</div> <div>Ed Rybicki, <i>University of Cape Town, South Africa</i></div> <div>INTRODUCTION TO 2026 ISV CONGRESS (Antwerp, Belgium)</div> <div>Michael Schotsaert, <i>Icahn School of Medicine at Mount Sinai, USA</i></div> |
| 17:30-19:30 | NEXT GENERATION VACCINOLOGIST ECR NETWORKING SOCIAL EVENT (Bridge 1- First Floor)                                                                                                                                                                                                                                          |